The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Comparative analysis of prostate‐specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group
Abstract
What's known on the subject? and What does the study add? Very few comparative studies to date evaluate the results of treatment options for prostate cancer using the most sensitive measurement tools. PSA has been identified as the most sensitive tool for measuring treatment effectiveness. To date, comprehensive unbiased reviews of all the current literature are limited for prostate cancer. This is the first large scale comprehensive review of the literature comparing risk stratified patients by treatment option and with long‐term follow‐up. The results of the studies are weighted, respecting the impact of larger studies on overall results. The study identified a lack of uniformity in reporting results amongst institutions and centres. A large number of studies have been conducted on the primary therapy of prostate cancer but very few randomized controlled trials have been conducted. The comparison of outcomes from individual studies involving surgery (radical prostatectomy or robotic radical prostatectomy), external beam radiation (EBRT) (conformal, intensity modulated radiotherapy, protons), brachytherapy, cryotherapy or high intensity focused ultrasound remains problematic due to the non‐uniformity of reporting results and the use of varied disease outcome endpoints. Technical advances in these treatments have also made long‐term comparisons difficult. The Prostate Cancer Results Study Group was formed to evaluate the comparative effectiveness of prostate cancer treatments. This international group conducted a comprehensive literature review to identify all studies involving treatment of localized prostate cancer published during 2000–2010. Over 18 000 papers were identified and a further selection was made based on the following key criteria: minimum/median follow‐up of 5 years; stratification into low‐, intermediate‐ and high‐risk groups; clinical and pathological staging; accepted standard definitions for prostate‐specific antigen failure; minimum patient number of 100 in each risk group (50 for high‐risk group). A statistical analysis (standard deviational ellipse) of the study outcomes suggested that, in terms of biochemical‐free progression, brachytherapy provides superior outcome in patients with low‐risk disease. For intermediate‐risk disease, the combination of EBRT and brachytherapy appears equivalent to brachytherapy alone. For high‐risk patients, combination therapies involving EBRT and brachytherapy plus or minus androgen deprivation therapy appear superior to more localized treatments such as seed implant alone, surgery alone or EBRT. It is anticipated that the study will assist physicians and patients in selecting treatment for men with newly diagnosed prostate cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The National Comprehensive Cancer Network: Present and future directions
McGivney, W. T. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19980515)82:10+<2057::aid-cncr14>3.0.co;2-a · Cited by 16,766
D'Amico, A. V. (1998) · JAMA · doi:10.1001/jama.280.11.969 · Cited by 4,523
Long-term results of the M.D. Anderson randomized dose-escalation trial for prostate cancer
Kuban, D. A., Tucker, S. L., Dong, L., Starkschall, G., Huang, E. H., Cheung, M. R., Lee, A. K., & Pollack, A. (2008) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2007.06.054 · Cited by 1,232
Zietman, A. L., DeSilvio, M. L., Slater, J. D., Rossi, C. J., Miller, D. W., Adams, J. A., & Shipley, W. U. (2005) · JAMA · doi:10.1001/jama.294.10.1233 · Cited by 1,224
Self-citationROEHL, K. A., HAN, M., RAMOS, C. G., ANTENOR, J. A. V., & CATALONA, W. J. (2004) · Journal of Urology · doi:10.1097/01.ju.0000134888.22332.bb · Cited by 861
Zietman, A. L., Bae, K., Slater, J. D., Shipley, W. U., Efstathiou, J. A., Coen, J. J., Bush, D. A., Lunt, M., Spiegel, D. Y., Skowronski, R., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.8475 · Cited by 735
Self-citationZELEFSKY, M. J., FUKS, Z., HUNT, M., LEE, H. J., LOMBARDI, D., LING, C. C., REUTER, V. E., VENKATRAMAN, E. S., & LEIBEL, S. A. (2001) · Journal of Urology · doi:10.1016/s0022-5347(05)65855-7 · Cited by 697
Self-citationWard, J. F., Slezak, J. M., Blute, M. L., Bergstralh, E. J., & Zincke, H. (2005) · British Journal of Urology · doi:10.1111/j.1464-410x.2005.05394.x · Cited by 473
Zelefsky, M. J., Chan, H., Hunt, M., Yamada, Y., Shippy, A. M., & Amols, H. (2006) · Journal of Urology · doi:10.1016/j.juro.2006.06.002 · Cited by 467
Self-citationKupelian, P. A., Potters, L., Khuntia, D., Ciezki, J. P., Reddy, C. A., Reuther, A. M., Carlson, T. P., & Klein, E. A. (2004) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(03)00784-3 · Cited by 457
Self-citation
Cited by
Mottet, N., Bellmunt, J., Bolla, M., Briers, E., Cumberbatch, M. G., De Santis, M., Fossati, N., Gross, T., Henry, A. M., Joniau, S., et al. (2017) · European Urology · doi:10.1016/j.eururo.2016.08.003 · Cited by 3,227
Mottet, N., van den Bergh, R. C. N., Briers, E., Van den Broeck, T., Cumberbatch, M. G., De Santis, M., Fanti, S., Fossati, N., Gandaglia, G., Gillessen, S., et al. (2021) · European Urology · doi:10.1016/j.eururo.2020.09.042 · Cited by 2,802
Cornford, P., van den Bergh, R. C. N., Briers, E., Van den Broeck, T., Brunckhorst, O., Darraugh, J., Eberli, D., De Meerleer, G., De Santis, M., Farolfi, A., et al. (2024) · European Urology · doi:10.1016/j.eururo.2024.03.027 · Cited by 1,246
Sooriakumaran, P., Nyberg, T., Akre, O., Haendler, L., Heus, I., Olsson, M., Carlsson, S., Roobol, M. J., Steineck, G., & Wiklund, P. (2014) · BMJ · doi:10.1136/bmj.g1502 · Cited by 258
Nicolae, A., Morton, G., Chung, H., Loblaw, A., Jain, S., Mitchell, D., Lu, L., Helou, J., Al-Hanaqta, M., Heath, E., et al. (2017) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2016.11.036 · Cited by 69
Metadata
- Authors
- Grimm, P., Billiet, I., Bostwick, D., Dicker, A. P., Frank, S., Immerzeel, J., Keyes, M., Kupelian, P., Lee, W. R., Machtens, S., Mayadev, J., Moran, B. J., Merrick, G., Millar, J., Roach, M., Stock, R., Shinohara, K., Scholz, M., Weber, E., Zietman, A., Zelefsky, M., Wong, J., Wentworth, S., Vera, R., & Langley, S.
- Venue
- BJU International
- Publisher
- Wiley
- Published
- 2012-01-12
- Volume
- 109
- Issue
- s1
- Pages
- 22-29
- ISSN
- 1464-4096 (ISSN-L)
- 1464-410X
- OpenAlex
- W1571792083
- Cited by
- 462
- References
- 37
- FWCI
- 43.16
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Comparative analysis of prostate‐specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group. https://app.cochat.ai/papers/10.1111/j.1464-410x.2011.10827.x
- The paper
- Grimm, P., Billiet, I., Bostwick, D., Dicker, A. P., Frank, S., Immerzeel, J., Keyes, M., Kupelian, P., Lee, W. R., Machtens, S., Mayadev, J., Moran, B. J., Merrick, G., Millar, J., Roach, M., Stock, R., Shinohara, K., Scholz, M., Weber, E., . . . Langley, S. (2012). Comparative analysis of prostate‐specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group. BJU International. https://doi.org/10.1111/j.1464-410x.2011.10827.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.